Literature DB >> 19828766

Prevalence of human papillomavirus 16 and 18 neutralizing antibodies in prenatal women in British Columbia.

Mel Krajden1, Karuna Karunakaran, Stacy So, Joel M Palefsky, Rachna Sharma, Darrel Cook, Amanda Yu, Ron Chow, Simon Dobson, Gina S Ogilvie, Martin Petric.   

Abstract

Human papillomavirus (HPV) type 16 and 18 neutralizing antibody (NAb) titers were measured in 1,020 prenatal women in British Columbia aged 15 to 39. HPV 16 and 18 NAbs were detected in 183/1,020 (17.9%) and 97/1,020 (9.5%), respectively, and 39 (3.8%) had NAbs to both types. Titers were similar across age strata.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19828766      PMCID： PMC2786386          DOI： 10.1128/CVI.00238-09

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN： 1556-679X


  16 in total

1.  Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection.

Authors:  J J Carter; L A Koutsky; J P Hughes; S K Lee; J Kuypers; N Kiviat; D A Galloway
Journal:  J Infect Dis       Date:  2000-05-31       Impact factor: 5.226

2.  Results of the first WHO international collaborative study on the standardization of the detection of antibodies to human papillomaviruses.

Authors:  Morag Ferguson; Alan Heath; Suzanne Johnes; Sonia Pagliusi; Joakim Dillner
Journal:  Int J Cancer       Date:  2006-03-15       Impact factor: 7.396

3.  Generation of HPV pseudovirions using transfection and their use in neutralization assays.

Authors:  Christopher B Buck; Diana V Pastrana; Douglas R Lowy; John T Schiller
Journal:  Methods Mol Med       Date:  2005

4.  Seroprevalence of human papillomavirus types 6, 11, 16, and 18 in the United States: National Health and Nutrition Examination Survey 2003-2004.

Authors:  Lauri E Markowitz; Maya Sternberg; Eileen F Dunne; Geraldine McQuillan; Elizabeth R Unger
Journal:  J Infect Dis       Date:  2009-10-01       Impact factor: 5.226

5.  Seroepidemiology of infection with human papillomavirus 16, in men and women attending sexually transmitted disease clinics in the United States.

Authors:  Deborah L Thompson; John M Douglas; Mark Foster; Michael E Hagensee; Carolyn Diguiseppi; Anna E Barón; Jennifer E Cameron; Timothy C Spencer; Jonathan Zenilman; C Kevin Malotte; Gail Bolan; Mary L Kamb; Thomas A Peterman
Journal:  J Infect Dis       Date:  2004-09-23       Impact factor: 5.226

6.  Population seroprevalence of human papillomavirus types 6, 11, 16, and 18 in men, women, and children in Australia.

Authors:  Anthony T Newall; Julia M L Brotherton; Helen E Quinn; Peter B McIntyre; Josephine Backhouse; Lynn Gilbert; Mark T Esser; Joanne Erick; Janine Bryan; Neil Formica; C Raina MacIntyre
Journal:  Clin Infect Dis       Date:  2008-06-01       Impact factor: 9.079

7.  Measurement of the humoral immune response following an incident human papillomavirus type 16 or 18 infection in young women by a pseudovirion-based neutralizing antibody assay.

Authors:  Jane Steele; Stuart Collins; Kaisheng Wen; Gordon Ryan; Christothea Constandinou-Williams; Ciaran B J Woodman
Journal:  Clin Vaccine Immunol       Date:  2008-07-16

8.  Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan.

Authors:  Jeffrey N Roberts; Christopher B Buck; Cynthia D Thompson; Rhonda Kines; Marcelino Bernardo; Peter L Choyke; Douglas R Lowy; John T Schiller
Journal:  Nat Med       Date:  2007-07-01       Impact factor: 53.440

9.  Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10000 women in Costa Rica.

Authors:  S S Wang; M Schiffman; T S Shields; R Herrero; A Hildesheim; M C Bratti; M E Sherman; A C Rodriguez; P E Castle; J Morales; M Alfaro; T Wright; S Chen; B Clayman; R D Burk; R P Viscidi
Journal:  Br J Cancer       Date:  2003-10-06       Impact factor: 7.640

10.  Seroprevalence of 34 human papillomavirus types in the German general population.

Authors:  Kristina M Michael; Tim Waterboer; Peter Sehr; Annette Rother; Ulrich Reidel; Heiner Boeing; Ignacio G Bravo; Jörg Schlehofer; Barbara C Gärtner; Michael Pawlita
Journal:  PLoS Pathog       Date:  2008-06-20       Impact factor: 6.823
View more
  6 in total

1.  Update on Human Papillomavirus (HPV) Vaccines: An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI) †.

Authors:  Dr M Dawar; Ms T Harris; Dr S McNeil
Journal:  Can Commun Dis Rep       Date:  2012-01-02

Review 2.  Age-specific human papillomavirus antibody and deoxyribonucleic acid prevalence: a global review.

Authors:  Sarah M Tiggelaar; Margaret J Lin; Raphael P Viscidi; Jia Ji; Jennifer S Smith
Journal:  J Adolesc Health       Date:  2012-02       Impact factor: 5.012

3.  Human papillomavirus 16 (HPV 16) and HPV 18 antibody responses measured by pseudovirus neutralization and competitive Luminex assays in a two- versus three-dose HPV vaccine trial.

Authors:  Mel Krajden; Darrel Cook; Amanda Yu; Ron Chow; Wendy Mei; Shelly McNeil; Deborah Money; Marc Dionne; Karuna P Karunakaran; Joel M Palefsky; Simon Dobson; Gina Ogilvie; Martin Petric
Journal:  Clin Vaccine Immunol       Date:  2011-01-19

4.  Immunization of mice by a multimeric L2-based linear epitope (17-36) from HPV type 16/18 induced cross reactive neutralizing antibodies.

Authors:  Farhad Motavalli Khiavi; Arash Arashkia; Maryam Nasimi; Mehdi Mahdavi; Majid Golkar; Farzin Roohvand; Kayhan Azadmanesh
Journal:  Res Pharm Sci       Date:  2017-08

5.  A Dual-Type L2 11-88 Peptide from HPV Types 16/18 Formulated in Montanide ISA 720 Induced Strong and Balanced Th1/Th2 Immune Responses, Associated with High Titers of Broad Spectrum Cross-Reactive Antibodies in Vaccinated Mice.

Authors:  Farhad Motavalli Khiavi; Arash Arashkia; Majid Golkar; Maryam Nasimi; Farzin Roohvand; Kayhan Azadmanesh
Journal:  J Immunol Res       Date:  2018-05-03       Impact factor: 4.818

6.  Respiratory syncytial virus-neutralizing serum antibody titers in infants following palivizumab prophylaxis with an abbreviated dosing regimen.

Authors:  Jennifer Claydon; Amitava Sur; Allison Callejas; Mihoko Ladd; Eddie Kwan; Richard Taylor; Stuart E Turvey; Alfonso Solimano; Pascal M Lavoie; Nico Marr
Journal:  PLoS One       Date:  2017-04-24       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.